Class of Antiretroviral Drugs and the Risk of Myocardial Infarction | Zendy

Nina FriisMøller | Zendy; Peter Reiss | Zendy; Caroline Sabin | Zendy; Rainer Weber | Zendy; Antonella d’Arminio Monforte | Zendy; Wafaa ElSadr | Zendy; Rodolphe Thiébaut | Zendy; Stéphane De Wit | Zendy; Ole Kirk | Zendy; Éric Fontas | Zendy; Matthew Law | Zendy; Andrew Phillips | Zendy; Jens Lundgren | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

Author(s) -

Nina FriisMøller,

Peter Reiss,

Caroline Sabin,

Rainer Weber,

Antonella d’Arminio Monforte,

Wafaa ElSadr,

Rodolphe Thiébaut,

Stéphane De Wit,

Ole Kirk,

Éric Fontas,

Matthew Law,

Andrew Phillips,

Jens Lundgren

Publication year - 2007

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa062744

Subject(s) - myocardial infarction , medicine , relative risk , incidence (geometry) , protease , confidence interval , reverse transcriptase inhibitor , infarction , prospective cohort study , cardiology , viral load , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , enzyme , biology , biochemistry , physics , optics

We have previously demonstrated an association between combination antiretroviral therapy and the risk of myocardial infarction. It is not clear whether this association differs according to the class of antiretroviral drugs. We conducted a study to investigate the association of cumulative exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors with the risk of myocardial infarction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research